Business Context and Reporting Period
Company: Arrowhead Research Corporation (f/k/a InterActive Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2007
Business Model: Development-stage nanotechnology company utilizing a portfolio approach. The Company operates five majority-owned subsidiaries focused on life sciences, electronics, and energy, and funds sponsored research at universities (e.g., Caltech, Duke, Stanford) to secure exclusive licensing rights to early-stage technologies.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 |
|---|---|---|
| Revenue | $1,208,022 | $595,458 |
| Cost of Goods Sold | $724,088 | $0 |
| Gross Profit | $483,934 | $595,458 |
| Operating Expenses | $38,433,106 | $21,078,840 |
| Operating Loss | $(37,949,172) | $(20,483,382) |
| Net Loss | $(29,931,118) | $(18,997,209) |
| Cash and Equivalents (End of Period) | $24,120,097 | $28,020,304 |
| Working Capital | $22,409,053 | $25,855,557 |
| Total Assets | $29,852,952 | $34,525,878 |
| Debt | $0 | $0 |
Note: The Company has no long-term debt. Revenue in 2007 included $326,427 from the sale of carbon nanotubes following the merger with Carbon Nanotechnologies, Inc. (CNI).
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $10.9 million (57%) compared to fiscal 2006. This was driven by a significant increase in operating expenses.
- Acquisition Impact: The April 2007 merger with CNI resulted in a non-cash charge of $9.6 million recorded as "Purchased in-process research and development."
- Staffing and R&D: Staffing nearly doubled due to the CNI merger and expansion of clinical trial preparations at subsidiaries Insert Therapeutics and Calando Pharmaceuticals. R&D expenses increased from $9.0 million to $20.9 million.
- Revenue Growth: Revenue doubled to $1.2 million, primarily due to the addition of CNI's carbon nanotube sales and funded research grants.
- Cash Position: Cash and cash equivalents decreased by approximately $3.9 million, reflecting the high burn rate associated with development activities.
Guidance, Outlook, and Risks
Outlook and Capital Needs: Management believes cash on hand ($24.1 million) is sufficient to fund operations through fiscal 2008. However, the Company expects losses to continue as it advances clinical trials and expands R&D. Future funding may be required through public/private financings or collaborations.
Key Subsidiary Milestones:
- Insert Therapeutics: Phase I clinical trials for IT-101 (anti-cancer) are ongoing; completion expected in 2008.
- Calando Pharmaceuticals: Preparing to file an Investigational New Drug (IND) application for CALAA-01 (RNAi therapeutic) in early 2008.
- Unidym: Generating revenue from carbon nanotube sales; developing transparent conductive films.
- Tego BioSciences: New subsidiary (acquired April 2007) focusing on fullerene-based antioxidants; received $2.4 million investment in October 2007.
Risks and Contingencies:
- Development Stage: No products are currently commercialized; significant time and capital required before revenue generation.
- Regulatory Approval: Success depends on FDA approvals for drug candidates, which are uncertain.
- Capital Commitments: The Company has an agreement to provide up to $6.0 million in additional capital to Calando Pharmaceuticals based on milestone achievement.
- Intellectual Property: Reliance on licensed university technology; risk of patent infringement claims or inability to enforce patents.
Investor Verification Checklist
- Cash Burn Rate: Verify the sufficiency of the $24.1 million cash balance against the projected $6.0 million commitment to Calando and ongoing R&D costs.
- Clinical Trial Progress: Monitor the status of Insert's IT-101 Phase I trials and Calando's IND filing timeline for 2008.
- Unidym Revenue Sustainability: Assess whether carbon nanotube sales from the CNI merger can scale to offset operating losses.
- Dilution Risk: Review outstanding options (approx. 5 million) and warrants (approx. 2.1 million) and the potential for future equity financings.
- Management Changes: Note the appointment of Christopher Anzalone as CEO (Dec 2007) and Larry Stambaugh as CEO of Insert/Calando (Nov 2007).